Ubie

Inference is the product. The system generates its next question from the user's prior answers rather than walking a fixed decision tree, drawing on a stated set of roughly 3,500 question data types, and returns a ranked set of possible causes across more than 1,000 diseases. Remove the model and there is no product left.

The tool outputs possible causes and a recommendation on whether and where to seek care, and it explicitly does not diagnose, which is the correct posture for a direct to consumer symptom checker. Oversight is editorial rather than in the loop: a stated panel of more than 50 physicians supervises the prediction pathway for each disease and a published medical content editorial policy governs review. That is supervision of the model's content ahead of use rather than review of an individual user's result, which is a meaningful distinction for a buyer.

Unusually specific about inputs and process, silent on architecture. The company publishes a clinical data sources page, names its supervising physicians individually with their institutions, and describes the algorithm as continuously refined since 2017 against real world data from a stated 1,700 provider organizations. What is not disclosed is the model architecture itself or whether any third party foundation model sits underneath, so a technical reviewer can audit the knowledge base and the human review process but not the system.

Among the strongest evidence postures in the consumer facing tier of this index, because the company publishes a number that can be checked and lost. It reports a Top-10 hit accuracy of 71.6 percent against a comparator average near 60 percent, links directly to the underlying medRxiv study, and the study design is disclosed as vignette based across 328 vignettes. Buyers should weigh two caveats: the study is a preprint rather than peer reviewed at the linked location, and vignette accuracy is not the same as accuracy on live undifferentiated patients.

The consumer product collects biological sex, age, and history including past illnesses and family history without requiring registration, and the company maintains published privacy, security, and information security policies plus a page describing its United States compliance posture. The reason this does not grade higher is that the disclosure is policy level rather than technical: no encryption, retention, or de identification specifics were located, and the data collected is sensitive by any standard.

No public statement of HIPAA covered entity or business associate status, and no BAA commitment was located. This is not necessarily a failure: a free direct to consumer symptom checker where the user enters their own information may sit outside HIPAA entirely, since HIPAA attaches to covered entities and their business associates rather than to health information generally. A provider organization considering the partner or embedded deployments would need to establish BAA availability directly, and should not assume it.

A published security policy and privacy policy exist, but no SOC 2, HITRUST, ISO 27001, or equivalent third party attestation was located in public materials.

No FDA clearance is claimed and none appears to be asserted as necessary. The product returns possible causes and a care seeking recommendation rather than a diagnosis, which is the positioning that generally keeps a symptom checker outside device regulation. Buyers deploying it in a clinical pathway rather than as consumer information should test that boundary themselves, since intended use is what determines the classification.

There is a real governance mechanism here, which is the documented medical content editorial policy and the named supervising physician panel spanning emergency medicine, internal medicine, neurology, psychiatry, and surgical specialties across multiple countries. What is absent is bias evaluation: no disclosure was located on accuracy variation across demographic groups, which matters because the questionnaire conditions on biological sex and age, and because a symptom checker's failure modes are rarely uniform across populations.

No EHR integration is evidenced for the consumer product. Distribution partnerships exist that embed the symptom checker into third party patient platforms, and the company references a large base of connected provider organizations, but no HL7, FHIR, or named EHR integration was located.

Web delivered and available without registration. No hosting, tenancy, or data residency disclosure was located, which is a gap worth closing for any non consumer deployment given the company operates across Japan, the United States, and other markets.

The consumer product's price is published and unambiguous: free, no registration, no credit card. That is full transparency on the surface most users touch. The enterprise surfaces, meaning pharmaceutical partnerships, provider distribution, and the embedded deployments, carry no published pricing, so an institutional buyer starts from zero.

Breadth is the design goal and it is substantiated: coverage spans more than 1,000 diseases with entry points organized by symptom, disease, body part, and specialty, including psychiatry, dermatology, neurology, ENT, and gastroenterology, and explicitly including mental health and women's health. The product operates in Japan, the United States, and additional markets with algorithms stated to be regionally customized for disease prevalence, which is a real localization commitment rather than translation.